Member access

4-Traders Homepage  >  Shares  >  Mercato Continuo Espanol  >  FAES Farma SA    FAE   ES0134950F36

FAES FARMA SA (FAE)

3
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mercato Continuo Espanol
12/11/2014 12/12/2014 12/15/2014 12/16/2014 12/17/2014 Date
1.85(c) 1.815(c) 1.735(c) 1.76(c) 1.75(c) Last
273 545 186 832 502 704 220 199 107 581 Volume
+0.27% -1.89% -4.41% +1.44% -0.57% Change
More quotes
Company
Faes Farma SA engages in the manufacture, marketing, and research of pharmaceutical products and raw materials for pharmaceutical use. Its products are for allergies, antihypertensive, dermatological, diabetes, digestive, otorhinolaryngology, osteoarticular, respiratory, women's health, central... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Surperformance© ratings of FAES Farma SA
Trading Rating : Investor Rating :
More Ratings
Chart FAES FARMA SA
Duration : Period :
FAES Farma SA Technical Analysis Chart | FAE | ES0134950F36 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 193 M
EBIT 2014 31,3 M
Net income 2014 25,5 M
Debt 2014 9,95 M
Yield 2014 3,28%
Sales 2015 205 M
EBIT 2015 37,1 M
Net income 2015 28,8 M
Finance 2015 7,84 M
Yield 2015 3,16%
PER 2014 15,87
PER 2015 13,36
EV / Sales 2014 2,18x
EV / Sales 2015 1,97x
Capitalization 411 M
More Financials
Latest news on FAES FARMA SA
05/15 FAES FARMA : Statement 05/14/2014 (112 k.). Bilastine in Canada: signing of a li..
05/14 FAES FARMA : Statement 05/14/2014 (112 k.). Bilastine in Canada: signing of a li..
2013 FAES FARMA SA : Statement 07/24/2013 (24 k.). January-June results.
2012 FAES FARMA SA : Statement 13/12/2012 (20 k). Faes Farma licences bilastine for S..
2012 FAES FARMA SA : Statement 02/07/2012 (19 k). FAES FARMA S.A. informs of the appr..
2012 FAES FARMA SA : ex-dividend day for final dividend
2012 FAES FARMA SA : Statement 26/04/2012 (28 k). FAES FARMA and INVIDA (MENARINI Gro..
2012 FAES FARMA SA : Statement 24/01/2012 (19 k). Bilastine's launch in Brazil.
More news
Sector news
17m ago ASTRAZENECA : LYNPARZA™ APPROVED IN THE EUROPEAN UNION
41m agoDJLONDON MARKETS : AstraZeneca, Oil Shares Contribute To FTSE 100's Advance
54m ago OTSUKA : Pharmaceutical acquires U.S. dietary supplement firm
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF